AP NEWS
Press release content from PR Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from PR Newswire
Press release content from PR Newswire. The AP news staff was not involved in its creation.

Regeneron to Report Fourth Quarter and Full Year 2019 Financial and Operating Results and Host Conference Call and Webcast on February 6, 2020

January 10, 2020 GMT

TARRYTOWN, N.Y., Jan. 10, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2019 financial and operating results on Thursday, February 6, 2020, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:00 AM Eastern Time that day.

Conference Call Information
To access this call, dial (800) 708-4540 (U.S.) or (847) 619-6397 (International). A link to the webcast may be accessed from the ‘Investors and Media’ page of Regeneron’s website at http://investor.regeneron.com/events.cfm. A replay of the conference call and webcast will be archived on the Company’s website for at least 30 days.

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, including VelocImmune® which uses a unique genetically-humanized mouse to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.


For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Contact Information:


Investor Relations

Corporate Communications

Justin Holko

Hala Mirza

914.847.7786

914.847.3422

justin.holko@regeneron.com

hala.mirza@regeneron.com

View original content: http://www.prnewswire.com/news-releases/regeneron-to-report-fourth-quarter-and-full-year-2019-financial-and-operating-results-and-host-conference-call-and-webcast-on-february-6-2020-300984444.html

SOURCE Regeneron Pharmaceuticals, Inc.